Fluoxymesterone steroidspowder(at)sinosteroids(dot)com
-
Post Date:
Oct 28,2015
-
Expiry Date:
Oct 27,2016
-
Detailed Description:
Cas No. :76-43-7
Quantity: 3000Kilograms
Specs:steroidspowder(at)sinosteroids(dot)com
Payment Method: western union,monygram, banktransfer, bitcoin
Fluoxymesterone
steroidspowder(at)sinosteroids(dot)com
CAS: 76-43-7
EINECS: 200-961-8
Molecular fomular:C20H29FO3
Molecular Weight:336.44
Molecular Structure:
Assay: 99% min.
Packing: foil bag or tin.
Delivery: Express courier.
Character: White crystalline powder. Mp 240℃, refractive index 104°.
Usage: pharmaceutical material, Steroid hormone, Anabolin. As a male hormone and anabolic hormones.
Description:
Stenox also known as Halotestin (fluoxymesterone), is a halogenated derivative of 17-alpha-methyltestosterone and has an extreme androgenic effect and a very slight anabolic effect. With this combination, a person can expect a great increase in muscle hardness and strength with no real gain in size or weight. Because of the very high androgenic effect, many athletes have reported high levels of aggression making their workouts extremely intense.
Competitive Advantage:
1. High quality with competitive price:
2 .Fast and safe delivery:
3. Good after-sales service.
4. We have clients throughout the world:
1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2) Market feedback and goods feedback will be appreciated, meeting customers' requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.
steroidspowder@sinosteroids.com
-
CAS Registry Number:
76-43-7
-
Synonyms:
;fluoxymesterone standard solution;fluoxymesterone--dea schedule iii;9-alpha-fluoro-11-beta,17-beta-dihydroxy-17-alpha-methylandrost-4-en-3-one;(11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one;
-
Molecular Formula:
C20H29FO3
-
Molecular Weight:
336.4409
-
Molecular Structure:
-
Safety Description:
S24/25:;
Inquiry